Fewer participants treated with SNG001 compared to placebo progressed to hospitalisation (1/110 vs 7/110, P=0.07) SNG001 was well-tolerated with a favourable safety profile consistent with
Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SCHAUMBURG, Ill., Feb. 12, 2021 /PRNewswire/ Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced today that Camostat mesilate (Camostat), is one of four therapies being added to the existing ACTIV-2 Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID), which was launched by the National Institutes of Health (NIH) and the AIDS Clinical Trials Group (ACTG) in May 2020.
ACTG was tasked with leading a Master Adaptive protocol under the Accelerating COVID-19 Therapeutic Interventions and Vaccine (ACTIV) partnership by Operation Warp Speed (OWS), the U.S. government s multi-agency effort to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. The ACTIV-2 trial will continue to evaluate monoclonal antibodies and other small molecules for outpatient COVID treatment. Camostat is the first orally administered agent to be included in the outpatient Adapt